Category Archives: Cancer Research

Mikhail Blagosklonny Research on Life Longitivity

Mikhail Blagosklonny is a philanthropist, researcher and an Oncology professor at the Roswell Park Cancer Institute since 2002. He works at the Department of Cell Stress Biology on cancer biomarkers and cell proliferation. He is a scientist and carries out research and studies on cancer and aging. He received an MD in Internal Medicine, cardiology, and Ph.D. in Experimental Medicine from the First Pavlov State Medical University of St. Petersburg. His research interests include Biogerontology, cancer, and its therapies and anti-aging drugs. He mostly targets the cancer therapies that protect the healthy living cells against any damage. He also works as Oncotarget’s Editor-in-chief.

He is a member of the editorial board of Cell Death and Differentiation. Mikhail Blagosklonny is the writer of aging Hyperfunction theory and has taken a very keen interest in oncology. He believes that it is possible to control aging and cure cancer without injuring the other normal body cells responsible for the recovering the body and mind of the patients after recovery. He came up with a proposal on the use of Rapamycin in cancer treatment and as an anti-aging drug. He also believes in a disease-free world that is why he has dedicated his time to research on best and cheaper cancer treatments so that everyone can be able to afford it. Mikhail Blagosklonny has over 300 publications under his name, and he is among the biggest researchers of oncology in the world. Furthermore, is a partner editor for the American Journal of Cancer, PLOS ONE, and International Journal of Cancer.

Mikhail is interested in cancer, aging, and the relationship between the two. He studies why cancer is most common in older people and uses the Rapamycin drug in increasing the life-span of the human beings. Rapamycin drug has numerous advantages in the medical field. It is used as an immunosuppressant during organ transplants as it is known to have a lower level of toxicity towards transplanted organs such as kidneys. It is also used in cancer treatment through improving and directing the immune system towards cancer tumors and cells. It also has the capability of reducing cancer in people with organ transplant.

Mikhail Blagosklonny is currently conducting research on how Rapamycin drug is increasing life-span of humans. He has carried out several tests on mice that have shown when mice are given the drug they have a higher immunity ability to fight diseases such as Tuberculosis. Several initial tests on humans have shown that the drug helps in the regeneration of cells and organs in elder people when they were injected with the drug prior to influenza vaccination. Scientists are currently carrying out research tests on the marmoset monkey to find out if the drug increases life-span. There are some research on the use of the Rapamycin drug on treatments of several diseases in humans. Initial test results on mice have proven to be very encouraging, and scientists have high hopes that the drug can be used on humans to increase life-span, treat Alzheimer’s disease, muscular dystrophy, and Systematic Lupus Erythematosus (SLE). Dr. Mikhail Blagosklonny has played a significant role in the pioneer of the research being carried out by the scientist.

How Eric Lefkofsky Helps Doctors Treat Cancer

Eric Lefkofsky is best known by most people as one of the co-founders of Groupon. More recently, though, he co-founded another firm called Tempus, Inc. This company is focused on helping doctors treat cancer and save lives. They offer doctors a genomic sequencing platform which allows them to individualize the cancer treatment they use to treat their patients. This leads to much better outcomes rather than the older and more conventional way of treating cancer.

Tempus was founded in 2015 and is based in Chicago, Illinois. They recently held a series C funding round and were able to bring in $70 million in funding in. The investors in this round were New Enterprise Associates and Revolution Growth. To date, Eric Lefkofsky and his business partner have raised a total of $130 million. Tempus is now valued at about $700 million. It was founded by Lefkofsky and a longtime business partner of his, Brad. Previously they had also teamed up when launching Groupon together.

Eric Lefkofsky serves at Tempus as the company’s Chief Executive Officer. He recognized that there was a need in the healthcare industry, in particular in regards to the methods by which clinical data collection was gathered. He knew that he could make improvements to this process which would result in doctors being better able to individually treat patients. With their background in technology, Lefkofsky and his team at Tempus use tech to put together a large amount of genomic and clinical data all together into one large database. Previously, information like this was spread out over different systems and databases.

Lefkofsky has been instrumental in establishing partnerships with a number of healthcare organizations. Among these are the Duke University School of Medicine, the Cleveland Clinic, and the Mayo Clinic. The goal is to create the largest molecular and clinical library in existence so that cancer care is improved around the world.

Eric Lefkofsky is a graduate of the University of Michigan. He earned his bachelor’s there in 1991 and his law degree at their law school in 1994. He has been an entrepreneur ever since, and has founded or co-founded several companies.

Eric Lefkofsky: CEO of Tempus and Known Philanthropist

Eric Lefkofsky is Co-Founder and CEO for Tempus; a company that helps patients in a clinical setting benefit from the treatment of others who came before them. As CEO of Tempus, Eric is helping to deliver personalized cancer care through interactive analytical and machine learning platform, which allows physicians to make real-time, data-driven decisions based on genomic sequencing and molecular analysis. Partnering with The University of Michigan; Tempus, is hoping to provide new solutions to people suffering from pancreatic cancer. Tempus also works to cure breast cancer and also hopes to begin building databases with information that can help people who suffer from all types of cancer eventually.

Before coming to Tempus, Eric Lefkofsky Co Founded Groupon, which connects millions of subscribers, worldwide, with local merchants by offering goods and services, travel, and activities in more than 28 countries. After leaving Groupon for other endeavors, Eric Co-Founded Lightbank, which specializes in making venture capital investments in what he terms “disruptive” technology companies in the U.S.A. Unlike many venture capitalist companies, Lightbank invests in companies all across the United States and not just those mainly found in Silicon Valley.

Eric Lefkofsky, a native of Chicago is a well-known philanthropist and has set up the Lefkofsky Family Foundation, which advances high impact initiatives, programs, and research that improves the quality of human life. For human rights it supports Americans for Responsible Solutions.

The Homestretch, Human Rights Watch, The Jewish United Fund, Medical Missions, for Children, Newtown: A Documentary, Personal PAC, Planned Parenthood, The Representation Project, and the RFK Center. For education it supports AUSL (Academy for Urban School Leadership), After School Matters, Citizen Schools, The Success Project, Teach for America, Young Women’s Leadership Charter School, Young Chicago Authors and more. For arts and culture it supports the Anderson Ranch Arts Center, Art Institute of Chicago, Aspen Art Museum, The Aspen Institute, Chicago Ideas, Museum of Contemporary Art, Museum of Science and Industry, Ravinia Festival, Steppenwolf Theater, and more. Eric and his wife also joined The Giving Pledge, which is is a campaign to encourage the wealthy people of the world to contribute their wealth to philanthropic causes to learn more: http://lefkofskyfoundation.com/ click here.

Clay Siegall And His Quest To Revolutionise Science

Clay Siegall co-founded Seattle Genetics in the year 1998, and he is the CEO, company’s President and board chairman. He trained to be a cancer specialist, and he built a center for scientific innovations, where research would be carried out, drugs created and patients assisted. The organization has grown to be a success, and now it has its branches in approximately 65 nations.

Previously, he worked with the Bristol-Myers Squibb Genetics Pharmaceuticals Research Institute and several other health organizations up to the year1997. He also served as a BOD in Ultragrnyx Pharmaceutical, and he has been on the receiving end of several awards like the University of Maryland Alumnus of the year for Computer, Math and Natural Science in 2013.

His recent achievements have been a result of his commitment to focussing on research and implementing cutting-edge research developments his desire to help patients have been the one driving him, and currently, he is motivated to eradicate their suffering.

He had demonstrated outstanding leadership qualities when he helped raise over $1.2 billion for Seattle Genetics. This large amount of cash has contributed to paving the way for the advancement in the searching for treatment of cancer using technology. Clay represents a very rare combination of leadership skills and scientific knowledge which he uses to advance to new levels.

Currently, Clay has approximately 15 patents and is showing no sign of slowing down. He is also an author and has published over 70 articles which are used by scientific and medical practitioners.

WordPress Blog

Clay Siegall has a blog where he expresses his thoughts on various matters. On his recent post, he addresses the use of fungal pesticides which he says that it offers a viable alternative to traditional chemicals because it is effective. This is because it works from the inside the body of the pest

He also talks about the issue of love of an isolated, exclusive garden snail, which to it he finds a partner. When a mirror is placed in front of the snail, it swirls in an anti-clockwise manner, and it reveals its sex organs, but there is no mating because the organs couldn’t join.